Brief: Mithra Pharmaceuticals Reports Compelling Initial Preclinical Data On Novel Tyrosine Kinase Inhibitors
02/03/2023 06:48
March 2 (Reuters) - Mithra Pharmaceuticals SA
MITRA.BR :
* COMPELLING INITIAL PRECLINICAL DATA IN ITS RESEARCH
COLLABORATION ON NOVEL TYROSINE KINASE INHIBITORS WITH BCI
PHARMA
* PRECLINICAL STUDIES CONFIRM BROAD POTENTIAL OF INNOVATIVE
AND
PROPRIETARY INHIBITORS OF CSF-1R TO TREAT DIFFERENT PATHOLOGIES
* FIRST CONCLUSIVE DATA REINFORCE MITHRA'S INTENT TO ACQUIRE
BCI
PHARMA'S IP RIGHTS
Source text for Eikon: ID:nNDL1TN4fr
Further company coverage: MITRA.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mithra Pharmaceuticals SA
See all newsBrief: Mithra Sells Estetra, Neuralis, Specific Assets To Gedeon Richter for EUR 175 Mln
Brief: Mithra Receives Additional EUR 2.5 Million To Advance Monetization
Brief: Mithra Secures Court Protection Measures To Advance Monetization Process
Brief: Mithra Pharmaceuticals Achieves LPR In Estetrol Skin Study
Brief: Mithra Applies To Liege Company Court For A "Transfer Under Judicial Supervision" For Mithra CDMO